Target Profile
```
Patient's age must be greater than or equal to 18 years.
Patient must have active diagnosis of HER2-positive carcinoma of breast.
Patient must have active diagnosis of Metastasis from malignant tumor of breast.
Patient must have procedure of whole brain radiation therapy within greater than or equal to 28 days.
Patient must have historical medication with ingredient trastuzumab.
Patient must have active medication with ingredient lapatinib.
Patient must have active diagnosis of CNS metastases.
Patient must have a health evaluation score of ECOG performance status grade:Prid:Pt:^Patient:Nom:Observed less than or equal to 2.
Patient must not be pregnant.
Patient must not be breastfeeding.
Patient must agree to use adequate contraceptive measures.
Patient must not be able to swallow oral medication.
Patient must not have historical medication with ingredient cabazitaxel.
Patient must not have procedure of Radiation therapy care.
Patient must not have active medication within drug class  ANTINEOPLASTIC HORMONES.
Patient must not have active medication with ingredient St. John wort.
Patient must not have active diagnosis of HIV infection.
Patient must not have active diagnosis of Hepatitis B.
Patient must not have active diagnosis of Viral hepatitis C.
Patient must not have active diagnosis of Congestive heart failure AND New York Heart Association Classification - Class III.
Patient must not have active diagnosis of Congestive heart failure AND New York Heart Association Classification - Class IV.
Patient must not have drug allergy to ingredient cabazitaxel.
Patient must not have allergy to substance polysorbate 80.
Patient must not have adverse event of Grade 2 Peripheral sensory neuropathy.
Patient must not have adverse event of Grade 3 Peripheral sensory neuropathy.
Patient must not have adverse event of Grade 4 Peripheral sensory neuropathy.
Patient must not have adverse event of Grade 5 Peripheral sensory neuropathy.
Patient must not have adverse event of Grade 2 Peripheral motor neuropathy.
Patient must not have adverse event of Grade 3 Peripheral motor neuropathy.
Patient must not have adverse event of Grade 4 Peripheral motor neuropathy.
Patient must not have adverse event of Grade 5 Peripheral motor neuropathy.
```
